RAPT Therapeutics, Inc. (RAPT)
- Previous Close
1.8500 - Open
1.8200 - Bid 2.1600 x 100
- Ask 2.2000 x 200
- Day's Range
1.8100 - 2.2592 - 52 Week Range
1.7300 - 27.3500 - Volume
406,826 - Avg. Volume
303,658 - Market Cap (intraday)
75.566M - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-3.1300 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
www.rapt.comRecent News: RAPT
View More
Performance Overview: RAPT
Trailing total returns as of 10/2/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RAPT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RAPT
View MoreValuation Measures
Market Cap
64.92M
Enterprise Value
-44.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.59
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.34%
Return on Equity (ttm)
-77.97%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-120.43M
Diluted EPS (ttm)
-3.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
114.84M
Total Debt/Equity (mrq)
5.24%
Levered Free Cash Flow (ttm)
-64.13M
Research Analysis: RAPT
View MoreCompany Insights: RAPT
RAPT does not have Company Insights
Research Reports: RAPT
View MoreDaily – Vickers Top Buyers & Sellers for 10/20/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/18/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/14/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.